NCT07621159尚未招募1 期
A Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy and Safety of HDM2017 in Combination With Standard of Care in Participants With Advanced Colorectal Cancer
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 120
- 试验地点
- 1
研究概览
简要总结
This is a phase Ib/II clinical study. All participants are patients with advanced colorectal cancer (CRC). The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of HDM2017 in combination with standard of care in patients with advanced CRC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be able and willing to provide written informed consent.
- •Male or female participants with age ≥ 18 years.
- •Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic colorectal adenocarcinoma.
- •Be able to provide archived tumor tissue during the screening period.
- •Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or
- •Life expectancy ≥3 months.
- •According to RECIST v1.1, participants must have at least one measurable lesion.
- •Has adequate organ function.
- •All subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 7 months after the last dose of study treatment.
- •Be willing and able to complete regular visits, treatment plans, laboratory tests, and other trial procedures.
排除标准
- •Participants who have previously received treatment with an anti-VEGFR tyrosine kinase inhibitor (TKI).
- •Participants who have previously received ADC therapy containing Top I inhibitors, or other drug therapy targeting the CDH17 target.
- •Participants with other malignant tumors within the past 5 years, other than the tumor being treated in this study, with the exception of locally cured tumors (such as basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix or breast).
- •Related AEs from prior therapy (except for alopecia and ≤Grade 2 sensory neuropathy) have not recovered to ≤Grade 1 or baseline level.
- •Known weight loss of >10% within 2 months before the first dose of study drug or other indicators showing severe malnutrition.
- •History of severe esophagogastric varicose vein, severe ulcer, gastrointestinal perforation, abdominal fistula, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months before the first dose.
- •Participants with current imaging or clinical evidence of significant gastrointestinal obstruction.
- •Participants with clinically significant bleeding symptoms within 1 month before the first IMP dose.
- •Participants with known active CNS metastasis.
- •Participants with cardiovascular/cerebrovascular disorder, symptoms, or manifestations.
- •Participants with active syphilis, history of human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or active hepatitis C virus (HCV), except for asymptomatic chronic hepatitis B or C virus carriers.
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Use of Preoperative Postbiotic Supplementation in Colorectal Cancer SurgeryNCT07268846AC Camargo Cancer Center164
招募中
2 期
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer PatientsNCT07314294Shanghai EpimAb Biotherapeutics Co., Ltd.54
招募中
1 期
A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal CancerNCT07349043Second Affiliated Hospital, School of Medicine, Zhejiang University42
招募中
1 期
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181NCT07446816Ganzhou Hemay Pharmaceutical Co., Ltd24
招募中
3 期
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)Metastatic Colorectal CancerNCT07549412EMD Serono Research & Development Institute, Inc.1,020